# Pan Cancer T

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pan-cancer-t-b-v

- Industry: Biotechnology
- Headquarters: Rotterdam, Netherlands
- Website: www.pancancer-t.com
- Total disclosed funding: $4.6M
- Latest round: Seed (Jul 11, 2024)
- Investors on record: 5

## About

Based in the Netherlands, Pan Cancer T B.V. is a biotechnology firm specializing in innovative T cell therapies aimed at treating various cancers through advanced TCR-T cell technology.Pan Cancer T B.V. was founded in 2020 in Rotterdam, Netherlands, focusing on the development of next-generation T cell therapies, specifically TCR-T cell therapy. The company has successfully completed three deals, with its most recent funding round occurring on July 11, 2024, when it raised EUR 4.25 million in Seed funding led by InnovationQuarter, along with participation from Erasmus MC Biomedical Fund, Swanbridge Capital, Thuja Capital, and Van Herk Group. The company is co-founded by Dora Hammerl and Reno Debets, with Rachel Abbott serving as CEO.Pan Cancer T specializes in next-generation T cell therapies, focusing on TCR-T cell therapy that leverages the immune system to identify and destroy cancer cells. Its core products are tailored to address a variety of cancers, enhancing treatment efficacy by employing engineered T cells to recognize specific cancer antigens. The company works collaboratively with research institutions and hospitals in North America and Europe, targeting oncologists and healthcare providers, while also aiming to expand into emerging markets with a demand for innovative cancer therapies.The revenue model of Pan Cancer T comprises partnerships with healthcare providers and research institutions for the distribution of its TCR-T cell therapy products. Transactions are conducted through direct engagements with hospitals and oncology centers, where treatment plans are customized for individual patient needs. The company may also engage in collaborative research agreements that foster the development of its therapies while generating additional funding. Revenue is derived from per-treatment fees for its therapies and ongoing partnerships for clinical trials and research initiatives, ensuring a steady revenue stream while advancing cancer treatment solutions.In July 2024, Pan Cancer T B.V. raised EUR 4.25 million in Seed funding to support the completion of preclinical studies for its lead TCR-T cell product, PCT1:CO-STIM, and advance its CMC activities. The company aims to introduce new products designed to effectively target cancer cells while expanding its market presence into emerging regions by 2025. This funding will enhance their research and development capabilities, creating value and mitigating risks associated with their lead product.

## Funding rounds

- Seed, Jul 11, 2024, $4.6M — Thuja Capital, Erasmus MC Biomedical Fund, Van Herk Group, InnovationQuarter, Swanbridge Capital
- Seed, Oct 28, 2021 — Thuja Capital, Erasmus MC Biomedical Fund, Van Herk Group, Swanbridge Capital
- Seed, Jan 1, 2021 — Erasmus MC Biomedical Fund, Van Herk Group, Swanbridge Capital

## Investors

- Erasmus MC Biomedical Fund (https://capitalatlas.ai/funds/erasmus-mc-biomedical-fund) — Seed
- Van Herk Group (https://capitalatlas.ai/funds/van-herk-group) — Seed
- Swanbridge Capital (https://capitalatlas.ai/funds/swanbridge-capital) — Seed
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Seed